Our TCR-T cell therapy harnesses the patient’s own immune system to fight against viral infections and related cancers.
Our TCR-T cells are engineered to target virus-derived peptides presented on MHC class I on cell surface.
Upon virus infection, viral proteins are expressed in the infected cells. These viral proteins are degraded into viral peptides and assembled with MHC class I to be presented onto the cell surface. These peptide-MHC I complexes on the infected cell surface are recognized by cytotoxic T cells, leading to the release of cytokines and triggering antiviral responses.
Upon virus infection, viral proteins are expressed in the infected cells. These viral proteins are degraded into viral peptides and assembled with MHC class I to be presented onto the cell surface. These peptide-MHC I complexes on the infected cell surface are recognized by cytotoxic T cells, leading to the release of cytokines and triggering antiviral responses.
1. The patient undergoes leukapheresis to isolate white blood cells.
2. T cells from the patient are expanded and activated in Lion TCR’s GMP cell production center.
3. Genetic material encoding our virus- or cancer-targeting TCR are introduced into the activated T cells by viral transduction or electroporation.
4. The patient’s T cells now express the relevant TCR that target virus-infected or virus-related cancer cells.
5. Following phenotypic and functional validation, the TCR engineered T cells are infused back to the patient.
Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3
Koh S et al. Gastroenterology (2018)
Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection
Kah J et al. Journal of Clinical Investigation (2017)
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient
Qasim W et al. Journal of Hepatology (2015)
T cell receptor-therapy in HBV-related hepatocellularcarcinoma
Bertoletti A et al. Oncoimmunology (2015)
Our library of TCRs recognizes viral peptides expressed on MHC Class I restricted for the Asian population.
We are actively extending our proprietary TCR therapy platform to target more viruses, particularly those prevalent in Asia, for example, HBV, EBV and CMV.
